Genomics

Dataset Information

0

Atypical B cells and impaired SARS-CoV-2 neutralisation following heterologous vaccination in the elderly


ABSTRACT: Age is a major risk factor for hospitalization and death after SARS-CoV-2 infection, even in vaccinees. Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here we show that individuals 70 or older who received a primary two dose schedule with AZD1222 and booster third dose with mRNA vaccine achieved significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared to those below 70 at one month post booster. Neither the concentration of serum binding anti spike IgG antibody, nor the frequency of spike- specific B cells showed differences by age grouping. Impaired neutralization potency and breadth post-third dose in the elderly was associated with enrichment of circulating “atypical†spike-specific B cells expressing CD11c and FCRL5. Presence of these atypical B cells was confirmed by scRNA seq. However, when considering individuals who received three doses of mRNA vaccine, we did not observe statistically significant differences in neutralization or enrichment in atypical B cells by age grouping following dose 3. Together, our data reveal impaired neutralising antibody responses in the elderly after heterologous vaccination with AdV followed by mRNA booster dose, but not in homologous three dose mRNA vaccination highlighting that different vaccine formats differentially instruct the memory B cell response.

PROVIDER: EGAS00001007385 | EGA |

REPOSITORIES: EGA

Similar Datasets

2022-03-09 | GSE190747 | GEO
| EGAS00001005380 | EGA
2024-04-01 | GSE210229 | GEO
2024-04-01 | GSE210228 | GEO
2024-04-01 | GSE210227 | GEO
2024-04-01 | GSE232423 | GEO
2023-03-01 | GSE223236 | GEO
2022-12-22 | GSE221319 | GEO
2022-12-22 | GSE221316 | GEO
2024-01-31 | GSE234008 | GEO